A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f

A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) is a phase 2/3, randomised interventional study registered as NCT07739186 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-08 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1; PD-1/VEGF Bispecific Antibody; Tislelizumab; Pemetrexed; Carboplatin; Cisplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. Primary outcome: Phase II: Objective Response Rate (ORR); Phase II: Investigator-assessed Progression-free Survival (PFS); Phase III: BICR-assessed Progression-free Survival (PFS). Lung eligibility wording from the registry: "Patients with locally advanced non-squamous non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.